Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug
China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...
CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology
Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...
CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Aurisco Pharmaceutical Passes US FDA cGMP Inspection at Jiangsu Plant
China-based Aurisco Pharmaceutical (SHA: 605116) has announced the successful completion of a current Good Manufacturing...
Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment
Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second...
Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...
CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform
US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...
Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law
Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...
Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...